LB Pharmaceuticals Inc LBRX
Set alert
39.70 USD -0.45 -1.12%
At close · Oct 30
40.20 +0.50 +1.26%
After hours · Oct 30, 4:15 PM ET
39.13 Day range 41.24
14.61 52-week range 49.48
- YTD
- +78.35%
- 1 year
- +143.86%
- Open
- 40.10
- Prev close
- 40.15
- Mkt cap
- 1.28B
- Vol
- 429.47K
- Avg vol
- 366.85K
- EPS
- 0.10
- P/E
- 397.00
- Div yield
- 0.00%
More statistics
- Low
- 39.13
- High
- 41.24
- Forward P/E
- -7.74
- Beta
- 0.00
- Short ratio
- 12.64
- Inst. own
- 102.37%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 41.53
- 200-d avg
- 32.47
- 1y target
- 58.00
2Y chart
Events in this range
- Nov 6, 2025Earnings: -0.61; estimate -0.57; surprise -7.02%
- Mar 26, 2026Earnings: -0.45; estimate -0.45; surprise 0%
- May 12, 2026Earnings: -0.67; estimate -0.75; surprise 10.67%
- Aug 11, 2026Earnings: -1.71; estimate -0.80366; surprise -112.78%
- Aug 12, 2026Rating: BMO Capital · Outperform → Outperform
- Aug 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 2, 2026Rating: Needham · — → Buy
- Oct 5, 2026Downgrade: Roth Capital · Buy → Neutral
- Oct 6, 2026Rating: Guggenheim · — → Buy
- Oct 9, 2026Rating: Canaccord Genuity · — → Buy
Signals (49)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 18, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | May 7, 2026 | 5 months ago |
| RSI: Overbought | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 25, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 2, 2026 | 10 months ago |
| MACD: Buy Signal | Dec 31, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| RSI: Overbought | Dec 8, 2025 | 10 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 17, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 6, 2025 | 12 months ago |
Key statistics
- Market cap
- 1.28B
- Enterprise value
- 972.63M
- Trailing P/E
- 397.00
- Forward P/E
- -7.74
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.43
- EPS (TTM)
- 0.10
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -53.92M
- Total cash
- 327.79M
- Total debt
- 5.22M
- Return on equity
- -50.00%
- Shares outstanding
- 32.26M
- Short % of float
- 20.29%
- 50-day average
- 41.53
- 200-day average
- 32.47
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 58.00 +46.1% upside
Now 39.70
- Target (low)
- 35.00
- Target (mean)
- 58.00
- Target (high)
- 80.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.52.
Financials — quick view
LBRX Revenue — quarterly 0
LBRX Net income — quarterly -51.60M
LBRX EPS — quarterly -1.71
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.62 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.80366 | -1.71 | -0.91 | -112.78% |
| May 12, 2026 | Mar 31, 2026 | -0.75 | -0.67 | +0.08 | +10.67% |
| Mar 26, 2026 | Dec 31, 2025 | -0.45 | -0.45 | 0.00 | 0.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.61 | -0.04 | -7.02% |
| Sep 8, 2025 | Jun 30, 2025 | — | -1.44 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | init | — | Buy |
| Oct 6, 2026 | Guggenheim | init | — | Buy |
| Oct 5, 2026 | Roth Capital | down | Buy | Neutral |
| Oct 2, 2026 | Needham | init | — | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2026 | BMO Capital | main | Outperform | Outperform |
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lbpharma.us
News
- LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
- LB Pharmaceuticals to Participate in Upcoming Investor Events
- Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
- Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65
- Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80
- LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
- Roth Capital Downgrades LB Pharmaceuticals to Neutral, Lowers Price Target to $35
- This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68
- LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62
Your note
Sign in to keep a note on LBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| NUSSBAUM RAN | Director | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
| VIDA VENTURES GP III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 10.39% | 3,352,804 | 133.11M | Jun 29, 2026 |
| Blackrock Inc. | 8.48% | 2,734,305 | 108.55M | Jun 29, 2026 |
| RA Capital Management, L.P. | 6.85% | 2,208,604 | 87.68M | Jun 29, 2026 |
| Trails Edge Capital Partners, LP | 4.72% | 1,523,022 | 60.46M | Jun 29, 2026 |
| Commodore Capital Lp | 4.65% | 1,500,000 | 59.55M | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 4.64% | 1,497,293 | 59.44M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 2.15% | 692,905 | 27.51M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.08% | 672,000 | 26.68M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.80% | 581,677 | 23.09M | Sep 29, 2026 |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 1.76% | 567,627 | 22.53M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.86% | 278,887 | 11.07M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.76% | 244,910 | 9.72M | Jul 30, 2026 |